Objective:To study the influence of gefitinib for the peripheal blood PD-L1,PD-1,Th1 and Th17 related indexes of patients with advanced lung cancer.Methods:Selected 66 cases of advanced lung adenocarcinoma,the EGFR gene were all mutationanl,and they were divided into control group 33 cases and observation group 33 cases according to different treatment methods,the control group were treated with conventional chemotherapy,the observation group were treated with gefitinib on the treatment of control group,then the serum PD-L1,PD-1,Th1 and Th17 related indexes of two groups before and after the treatment were detected with ELISA method.Results:The serum PD-L1,PD-1,Th1 and Th17 related indexes of two groups before the treatment were compared,all P>0.05,while the serum PD-L1 and PD-1 of observation group at different time after the treatment were all lower than those of control group,serum Th1 and Th17 related indexes were all significantly better than those of control group,all P<0.05,the differences between the two groups were all significant.Conclusion:The influence of gefitinib for the PD-L1,PD-1,Th1 and Th17 related indexes of patients with advanced lung cancer is more active,so its immunoregulation role in the patients with advanced lung cancer is obvious.%目的:研究吉非替尼对晚期肺癌患者外周血PD-L1、PD-1及Th1、Th17相关指标的影响.方法:选取晚期肺腺癌患者66例,EGFR基因检测均有突变,按治疗方法不同将其分为对照组33例和观察组33例;对照组进行含铂两药联合化疗,观察组为含铂两药联合化疗加吉非替尼治疗.采用酶联免疫吸附试验(ELISA法)检测并分析两组治疗前后外周血PD-L1、PD-1及Th1、Th17相关指标变化.结果:治疗前两组患者的外周血PD-L1、PD-1及Th1、Th17相关指标对比无统计学差异(P均>0.05),但治疗后观察组的外周血PD-L1及PD-1均低于对照组,Th1及Th17相关指标也均显著地优于对照组,差异有统计学意义(P均<0.05).结论:吉非替尼对晚期肺癌患者PD-L1、PD-1及Th1、Th17相关指标的影响较为积极,在晚期肺癌患者中的免疫调节作用明显.
展开▼
